论文部分内容阅读
应用HAg 18-1 ELIsA诊断药盒,对原发性肝癌(PHc)、肝炎及肝炎伴有肝硬化、其他癌(肺癌、胃癌、结肠癌)以及正常人,共400例,进行了血清学的检测。结果显示:HAg 18-1 ELISA阳性检测率,PHC为81％,肝炎及伴有肝硬化为30％,肺癌为36％,胃癌为28％,结肠癌为12％,正常人为0。PHC组HAg 18-1 ELISA检测阳性率显著高于其他各组(P<0.05)。此外PHC 80例中有56例同时伴有AFP的检测,其中AFP 17/56阴性,17例阴性中HAg 18-1 ELISA检测阳性10例(59％),故对AFP检测PHC具有明显协同和补充诊断价值。此药盒操作简便,易于推扩,对PHC的临床诊断和普查提供了新方法。
Using the HAg 18-1 ELIsA diagnostic kit, a total of 400 patients with primary liver cancer (PHc), hepatitis and hepatitis associated with cirrhosis, other cancers (lung, gastric cancer, colon cancer), and normal persons were serologically studied. Testing. The results showed that HAg 18-1 ELISA positive detection rate, PHC was 81%, hepatitis and cirrhosis with 30%, lung cancer was 36%, gastric cancer was 28%, colon cancer was 12%, normal people were 0. The positive rate of HAg 18-1 ELISA in PHC group was significantly higher than that in other groups (P<0.05). In addition, 56 out of 80 cases of PHC were accompanied by AFP, of which AFP was 17/56 negative, and 17 cases of negative HAg 18-1 ELISA were positive in 10 cases (59%). Therefore, there was obvious synergy and supplementation for AFP detection of PHC. Diagnostic value. The kit is easy to operate, easy to expand and expand, and provides a new method for clinical diagnosis and screening of PHC.